Tarceva Price Will Be Bounded By Iressa And Gleevec, OSI Says

 
• By Adam Eckstein

The dose and pharmacokinetic profile of Tarceva allow for premium pricing over AstraZeneca's Iressa, OSI CEO Colin Goddard says. Approval of Tarceva for the treatment of non-small cell lung cancer possible by late January.

More from Archive

More from Pink Sheet